About Wild-Type ATTR Cardiac Amyloidosis
Wild-type ATTR cardiac amyloidosis is a spontaneous age-related disease where normal transthyretin protein becomes unstable and misfolds into amyloid fibrils that accumulate in cardiac tissue. Unlike hereditary ATTR, no genetic mutation causes the disease. The condition creates restrictive cardiomyopathy with preserved ejection fraction, producing prominent right-sided heart failure symptoms including lower extremity edema and fluid retention.
Cardiac manifestations include increased wall thickness, restrictive filling patterns, and frequent atrial fibrillation (affecting 40 to 60% of patients). Importantly, carpal tunnel syndrome often appears about 9 years before the heart disease is diagnosed, providing a potential window for early diagnosis. The disease predominantly affects very elderly males, yet remains profoundly underdiagnosed as symptoms are often attributed to other common conditions.
Most people are diagnosed without a biopsy. Once blood and urine tests (serum free light chains and immunofixation) rule out AL amyloidosis, a PYP, DPD or HMDP bone scan showing grade 2 or 3 heart uptake confirms ATTR, and TTR gene sequencing then shows whether it is wild-type or hereditary. A biopsy is needed when the light chain tests are abnormal or the scan is unclear. Recent studies suggest wild-type ATTR may account for 5 to 10% of heart failure cases in elderly populations.
Common Symptoms of Wild-Type ATTR Cardiac Amyloidosis
Recognizing the signs of Wild-Type ATTR Cardiac Amyloidosis early can lead to faster diagnosis and better outcomes. Symptoms may vary in severity from person to person. If you or a loved one are experiencing any of the following, consider speaking with a specialist.
- Shortness of breath and exercise intolerance
- Leg and ankle swelling
- Fatigue and weakness
- Irregular heartbeat or palpitations
- Fainting or near-fainting from conduction abnormalities
- Carpal tunnel syndrome (often about 9 years before the heart disease is diagnosed)
Who Wild-Type ATTR Cardiac Amyloidosis Affects
Wild-type ATTR predominantly affects males over 60 years old, with mean age of symptom onset around 80 years. Male predominance ranges from 75 to 91% in clinical populations. Female cases are increasingly recognized but remain less common.
Find Your Next Step
FDA-Approved Treatments for Wild-Type ATTR Cardiac Amyloidosis
There are currently 3 FDA-approved medications for Wild-Type ATTR Cardiac Amyloidosis. These therapies represent the current standard of care and may be used alongside or compared against investigational treatments in active clinical trials.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
Wild-Type ATTR Cardiac Amyloidosis Medicines in Clinical Trials
Investigational medicines Trial Friend tracks for Wild-Type ATTR Cardiac Amyloidosis, with trial results, safety findings and where each one stands.
Help Paying for Wild-Type ATTR Cardiac Amyloidosis Treatment
Charity funds and drugmaker programs for Wild-Type ATTR Cardiac Amyloidosis, checked at the source.
- From a charity · HealthWell FoundationAmyloidosis fundOpen
Pays for: Copays, premiums or other treatment costs.
- From a charity · HealthWell FoundationCardiomyopathy (Medicare Access) fundOpen
Pays for: Copays, premiums or other treatment costs. Medicare patients only.
- From a charity · NORD RareCareAmyloidosis Medical Assistance fundOpen
Pays for: Medical and medication costs.
The foundation says: “Accepting Applications” - From a charity · NORD RareCareAmyloidosis Premium Copay Assistance fundOpen
Pays for: Insurance premiums and copays.
The foundation says: “Accepting Applications” - From a charity · TotalAssist (formerly PAN Foundation)Amyloidosis fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $5,500 per year. Requires Medicare, Medicaid or TRICARE.
- From a charity · The Assistance FundAmyloidosis fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
The foundation says: “WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists a…”
- Amvuttra (Vutrisiran) · Alnylam Assist
- Vyndamax (Tafamidis) · VynAssist / VyndaLink
- Attruby (Acoramidis) · ForgingBridges
Side Effect Explorer
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Genetic Testing
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Wild-Type ATTR Cardiac Amyloidosis Resources
Reputable organizations and medical references for learning more about Wild-Type ATTR Cardiac Amyloidosis, including disease registries, foundation resources, and clinical guidelines.